alliance pharmaceuticals limited
alliance pharmaceuticals limited Company Information
Company Number
03250064
Next Accounts
Sep 2025
Shareholders
alliance pharma plc
Group Structure
View All
Industry
Manufacture of other food products n.e.c.
+1Registered Address
avonbridge house bath road, chippenham, wiltshire, SN15 2BB
Website
www.alliancepharma.co.ukalliance pharmaceuticals limited Estimated Valuation
Pomanda estimates the enterprise value of ALLIANCE PHARMACEUTICALS LIMITED at £380.4m based on a Turnover of £125.2m and 3.04x industry multiple (adjusted for size and gross margin).
alliance pharmaceuticals limited Estimated Valuation
Pomanda estimates the enterprise value of ALLIANCE PHARMACEUTICALS LIMITED at £0 based on an EBITDA of £-30.6m and a 15.55x industry multiple (adjusted for size and gross margin).
alliance pharmaceuticals limited Estimated Valuation
Pomanda estimates the enterprise value of ALLIANCE PHARMACEUTICALS LIMITED at £34.6m based on Net Assets of £17.6m and 1.97x industry multiple (adjusted for liquidity).
Edit your figures and get a professional valuation report.
Alliance Pharmaceuticals Limited Overview
Alliance Pharmaceuticals Limited is a live company located in wiltshire, SN15 2BB with a Companies House number of 03250064. It operates in the manufacture of other food products n.e.c. sector, SIC Code 10890. Founded in September 1996, it's largest shareholder is alliance pharma plc with a 100% stake. Alliance Pharmaceuticals Limited is a mature, mega sized company, Pomanda has estimated its turnover at £125.2m with healthy growth in recent years.
Upgrade for unlimited company reports & a free credit check
Alliance Pharmaceuticals Limited Health Check
Pomanda's financial health check has awarded Alliance Pharmaceuticals Limited a 3.5 rating. We use a traffic light system to show it exceeds the industry average on 5 measures and has 6 areas for improvement. Company Health Check FAQs
5 Strong
1 Regular
6 Weak
Size
annual sales of £125.2m, make it larger than the average company (£29.5m)
£125.2m - Alliance Pharmaceuticals Limited
£29.5m - Industry AVG
Growth
3 year (CAGR) sales growth of 5%, show it is growing at a slower rate (6.1%)
5% - Alliance Pharmaceuticals Limited
6.1% - Industry AVG
Production
with a gross margin of 60.5%, this company has a lower cost of product (29%)
60.5% - Alliance Pharmaceuticals Limited
29% - Industry AVG
Profitability
an operating margin of -31.3% make it less profitable than the average company (6.3%)
-31.3% - Alliance Pharmaceuticals Limited
6.3% - Industry AVG
Employees
with 198 employees, this is above the industry average (106)
198 - Alliance Pharmaceuticals Limited
106 - Industry AVG
Pay Structure
on an average salary of £84.4k, the company has a higher pay structure (£55k)
£84.4k - Alliance Pharmaceuticals Limited
£55k - Industry AVG
Efficiency
resulting in sales per employee of £632.4k, this is more efficient (£308.9k)
£632.4k - Alliance Pharmaceuticals Limited
£308.9k - Industry AVG
Debtor Days
it gets paid by customers after 102 days, this is later than average (50 days)
102 days - Alliance Pharmaceuticals Limited
50 days - Industry AVG
Creditor Days
its suppliers are paid after 100 days, this is slower than average (39 days)
100 days - Alliance Pharmaceuticals Limited
39 days - Industry AVG
Stock Days
it holds stock equivalent to 113 days, this is more than average (80 days)
113 days - Alliance Pharmaceuticals Limited
80 days - Industry AVG
Cash Balance
has cash to cover current liabilities for 8 weeks, this is average cash available to meet short term requirements (9 weeks)
8 weeks - Alliance Pharmaceuticals Limited
9 weeks - Industry AVG
Debt Level
it has a ratio of liabilities to total assets of 95.2%, this is a higher level of debt than the average (50.3%)
95.2% - Alliance Pharmaceuticals Limited
50.3% - Industry AVG
ALLIANCE PHARMACEUTICALS LIMITED financials
Alliance Pharmaceuticals Limited's latest turnover from December 2023 is £125.2 million and the company has net assets of £17.6 million. According to their latest financial statements, Alliance Pharmaceuticals Limited has 198 employees and maintains cash reserves of £7.8 million as reported in the balance sheet.
Data source: Companies House, Pomanda Estimates
| Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | Dec 2013 | Dec 2012 | Dec 2011 | Dec 2010 | Dec 2009 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Turnover | 125,207,000 | 116,018,000 | 121,112,000 | 109,114,000 | 104,925,000 | 94,580,000 | 79,645,000 | 55,575,000 | 47,390,000 | 43,913,000 | 44,976,000 | 42,377,000 | 44,145,000 | 48,007,000 | 29,795,000 |
| Other Income Or Grants | |||||||||||||||
| Cost Of Sales | 49,525,000 | 45,223,000 | 39,458,000 | 40,088,000 | 41,379,000 | 38,720,000 | 36,656,000 | 23,787,000 | 19,259,000 | 18,593,000 | 17,926,000 | 18,256,000 | 20,440,000 | 18,450,000 | 12,333,000 |
| Gross Profit | 75,682,000 | 70,795,000 | 81,654,000 | 69,026,000 | 63,546,000 | 55,860,000 | 42,989,000 | 31,788,000 | 28,131,000 | 25,320,000 | 27,050,000 | 24,121,000 | 23,705,000 | 29,557,000 | 17,462,000 |
| Admin Expenses | 114,874,000 | 57,614,000 | 63,578,000 | 54,710,000 | 32,790,000 | 34,438,000 | 16,649,000 | 15,155,000 | 11,270,000 | 14,291,000 | 13,048,000 | 12,116,000 | 11,379,000 | 10,804,000 | 6,360,000 |
| Operating Profit | -39,192,000 | 13,181,000 | 18,076,000 | 14,316,000 | 30,756,000 | 21,422,000 | 26,340,000 | 16,633,000 | 16,861,000 | 11,029,000 | 14,002,000 | 12,005,000 | 12,326,000 | 18,753,000 | 11,102,000 |
| Interest Payable | 27,297,000 | 13,773,000 | 9,732,000 | 9,265,000 | 10,419,000 | 8,380,000 | 6,833,000 | 8,130,000 | 4,015,000 | 2,847,000 | 2,536,000 | 2,424,000 | 2,306,000 | 2,842,000 | 3,726,000 |
| Interest Receivable | 2,291,000 | 7,185,000 | 2,956,000 | 674,000 | 763,000 | 3,467,000 | 2,218,000 | 139,000 | 48,000 | 50,000 | 48,000 | 49,000 | 54,000 | 52,000 | |
| Pre-Tax Profit | -64,198,000 | 6,593,000 | 17,361,000 | 5,051,000 | 21,413,000 | 21,378,000 | 22,974,000 | 6,819,000 | 12,345,000 | 8,329,000 | 11,827,000 | 10,414,000 | 10,220,000 | 13,326,000 | 4,943,000 |
| Tax | 4,312,000 | -1,257,000 | -7,518,000 | -2,858,000 | -3,846,000 | -2,382,000 | -4,883,000 | -1,807,000 | -2,170,000 | -1,768,000 | -2,459,000 | -2,104,000 | -2,076,000 | -3,918,000 | -1,469,000 |
| Profit After Tax | -59,886,000 | 5,336,000 | 9,843,000 | 2,193,000 | 17,567,000 | 18,996,000 | 18,091,000 | 5,012,000 | 10,175,000 | 6,561,000 | 9,368,000 | 8,310,000 | 8,144,000 | 9,408,000 | 3,474,000 |
| Dividends Paid | 2,600,000 | 2,800,000 | 7,596,000 | 5,600,000 | 5,720,000 | 1,730,000 | 5,700,000 | ||||||||
| Retained Profit | -59,886,000 | 5,336,000 | 7,243,000 | -607,000 | 9,971,000 | 13,396,000 | 12,371,000 | 3,282,000 | 4,475,000 | 6,561,000 | 9,368,000 | 8,310,000 | 8,144,000 | 9,408,000 | 3,474,000 |
| Employee Costs | 16,716,000 | 15,454,000 | 17,730,000 | 14,592,000 | 13,926,000 | 11,852,000 | 9,388,000 | 8,363,000 | 7,303,000 | 4,948,000 | 5,141,000 | 5,009,000 | 4,429,000 | 3,756,000 | 2,779,000 |
| Number Of Employees | 198 | 184 | 179 | 153 | 146 | 138 | 123 | 104 | 83 | 72 | 67 | 60 | 56 | 45 | 31 |
| EBITDA* | -30,646,000 | 21,931,000 | 25,964,000 | 21,132,000 | 31,757,000 | 22,509,000 | 27,169,000 | 16,996,000 | 17,097,000 | 12,445,000 | 14,690,000 | 12,852,000 | 13,324,000 | 19,743,000 | 11,226,000 |
* Earnings Before Interest, Tax, Depreciation and Amortisation
| Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | Dec 2013 | Dec 2012 | Dec 2011 | Dec 2010 | Dec 2009 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Tangible Assets | 2,043,000 | 1,763,000 | 4,207,000 | 14,434,000 | 9,729,000 | 6,620,000 | 4,689,000 | 1,396,000 | 805,000 | 396,000 | 592,000 | 564,000 | 3,925,000 | 4,048,000 | 3,292,000 |
| Intangible Assets | 185,639,000 | 221,061,000 | 224,560,000 | 222,846,000 | 240,291,000 | 243,504,000 | 189,626,000 | 113,078,000 | 109,042,000 | 87,471,000 | 85,707,000 | 76,531,000 | 62,771,000 | 56,928,000 | 41,576,000 |
| Investments & Other | 62,013,000 | 63,557,000 | 114,617,000 | 32,523,000 | 33,508,000 | 29,688,000 | 30,933,000 | 92,849,000 | 92,493,000 | 3,773,000 | 3,717,000 | 3,274,000 | 3,160,000 | 3,160,000 | 3,160,000 |
| Debtors (Due After 1 year) | 22,735,000 | 73,121,000 | 300,000 | 550,000 | |||||||||||
| Total Fixed Assets | 272,430,000 | 359,502,000 | 343,684,000 | 270,353,000 | 283,528,000 | 279,812,000 | 225,248,000 | 207,323,000 | 202,340,000 | 91,640,000 | 90,016,000 | 80,369,000 | 66,696,000 | 60,976,000 | 44,868,000 |
| Stock & work in progress | 15,364,000 | 13,831,000 | 15,761,000 | 16,606,000 | 12,476,000 | 15,528,000 | 11,983,000 | 10,620,000 | 7,403,000 | 5,914,000 | 5,463,000 | 5,388,000 | 5,652,000 | 4,544,000 | 2,973,000 |
| Trade Debtors | 35,067,000 | 33,548,000 | 17,343,000 | 15,249,000 | 18,128,000 | 15,744,000 | 12,163,000 | 10,405,000 | 8,128,000 | 6,822,000 | 9,094,000 | 8,893,000 | 7,407,000 | 8,675,000 | 6,695,000 |
| Group Debtors | 29,626,000 | 16,263,000 | 18,154,000 | 208,870,000 | 81,947,000 | 69,378,000 | 44,811,000 | 28,373,000 | 18,282,000 | 907,000 | 523,000 | 338,000 | 302,000 | 354,000 | 484,000 |
| Misc Debtors | 2,732,000 | 2,727,000 | 4,514,000 | 4,532,000 | 6,331,000 | 4,820,000 | 3,507,000 | 1,815,000 | 1,346,000 | 917,000 | 1,292,000 | 475,000 | 466,000 | 488,000 | 328,000 |
| Cash | 7,755,000 | 17,690,000 | 20,410,000 | 19,274,000 | 10,700,000 | 6,955,000 | 8,731,000 | 2,553,000 | 2,483,000 | 1,356,000 | 549,000 | 4,365,000 | 894,000 | 1,591,000 | 577,000 |
| misc current assets | 1,232,000 | 157,000 | 64,000 | 295,000 | 697,000 | 1,205,000 | 1,343,000 | 541,000 | 194,000 | ||||||
| total current assets | 91,776,000 | 84,216,000 | 76,246,000 | 264,826,000 | 130,279,000 | 112,425,000 | 82,400,000 | 55,109,000 | 38,183,000 | 16,110,000 | 16,921,000 | 19,459,000 | 14,721,000 | 15,652,000 | 11,057,000 |
| total assets | 364,206,000 | 443,718,000 | 419,930,000 | 535,179,000 | 413,807,000 | 392,237,000 | 307,648,000 | 262,432,000 | 240,523,000 | 107,750,000 | 106,937,000 | 99,828,000 | 81,417,000 | 76,628,000 | 55,925,000 |
| Bank overdraft | 68,035,000 | 41,719,000 | 25,782,000 | 15,776,000 | 3,309,000 | 5,021,000 | 6,251,000 | 683,000 | |||||||
| Bank loan | 4,250,000 | 4,000,000 | 3,114,000 | ||||||||||||
| Trade Creditors | 13,604,000 | 11,865,000 | 5,234,000 | 8,105,000 | 3,664,000 | 6,700,000 | 5,081,000 | 1,153,000 | 740,000 | 1,693,000 | 1,100,000 | 885,000 | 1,138,000 | 3,533,000 | 1,501,000 |
| Group/Directors Accounts | 22,986,000 | 11,530,000 | 9,566,000 | 292,602,000 | 238,865,000 | 208,526,000 | 150,719,000 | 122,607,000 | 114,479,000 | 47,965,000 | 42,739,000 | 33,161,000 | |||
| other short term finances | 413,000 | 47,000 | 500,000 | 834,000 | 2,889,000 | ||||||||||
| hp & lease commitments | 201,000 | 200,000 | 249,000 | 239,000 | 239,000 | 239,000 | 221,000 | 1,000 | |||||||
| other current liabilities | 11,808,000 | 20,264,000 | 24,354,000 | 12,386,000 | 11,110,000 | 10,016,000 | 8,684,000 | 12,015,000 | 13,822,000 | 5,928,000 | 8,266,000 | 20,072,000 | 41,975,000 | 43,522,000 | 28,542,000 |
| total current liabilities | 49,012,000 | 43,859,000 | 39,403,000 | 313,332,000 | 253,925,000 | 294,016,000 | 207,258,000 | 164,446,000 | 144,817,000 | 58,895,000 | 57,126,000 | 60,369,000 | 47,363,000 | 51,056,000 | 33,840,000 |
| loans | 287,075,000 | 305,598,000 | 289,050,000 | 142,133,000 | 80,148,000 | 29,106,000 | 45,652,000 | 59,547,000 | 60,473,000 | 19,364,000 | 20,881,000 | 20,225,000 | 30,450,000 | 30,000,000 | 38,018,000 |
| hp & lease commitments | 1,490,000 | 1,676,000 | |||||||||||||
| Accruals and Deferred Income | 3,803,000 | 1,450,000 | |||||||||||||
| other liabilities | 40,000 | 73,000 | 931,000 | ||||||||||||
| provisions | 10,520,000 | 15,778,000 | 17,245,000 | 13,160,000 | 12,819,000 | 11,147,000 | 10,093,000 | 7,943,000 | 7,798,000 | 6,536,000 | 6,683,000 | 6,705,000 | 9,148,000 | 1,282,000 | |
| total long term liabilities | 297,595,000 | 321,376,000 | 306,295,000 | 155,293,000 | 92,967,000 | 41,743,000 | 57,421,000 | 67,490,000 | 68,271,000 | 25,900,000 | 27,564,000 | 26,930,000 | 19,839,000 | 19,517,000 | 21,390,000 |
| total liabilities | 346,607,000 | 365,235,000 | 345,698,000 | 468,625,000 | 346,892,000 | 335,759,000 | 264,679,000 | 231,936,000 | 213,088,000 | 84,795,000 | 84,690,000 | 87,299,000 | 67,202,000 | 70,573,000 | 55,230,000 |
| net assets | 17,599,000 | 78,483,000 | 74,232,000 | 66,554,000 | 66,915,000 | 56,478,000 | 42,969,000 | 30,496,000 | 27,435,000 | 22,955,000 | 22,247,000 | 12,529,000 | 14,215,000 | 6,055,000 | 695,000 |
| total shareholders funds | 17,599,000 | 78,483,000 | 74,232,000 | 66,554,000 | 66,915,000 | 56,478,000 | 42,969,000 | 30,496,000 | 27,435,000 | 22,955,000 | 22,247,000 | 12,529,000 | 14,215,000 | 6,055,000 | 695,000 |
| Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | Dec 2013 | Dec 2012 | Dec 2011 | Dec 2010 | Dec 2009 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | |||||||||||||||
| Operating Profit | -39,192,000 | 13,181,000 | 18,076,000 | 14,316,000 | 30,756,000 | 21,422,000 | 26,340,000 | 16,633,000 | 16,861,000 | 11,029,000 | 14,002,000 | 12,005,000 | 12,326,000 | 18,753,000 | 11,102,000 |
| Depreciation | 572,000 | 888,000 | 709,000 | 999,000 | 824,000 | 876,000 | 553,000 | 271,000 | 236,000 | 307,000 | 266,000 | 274,000 | 263,000 | 178,000 | 124,000 |
| Amortisation | 7,974,000 | 7,862,000 | 7,179,000 | 5,817,000 | 177,000 | 211,000 | 276,000 | 92,000 | 1,109,000 | 422,000 | 573,000 | 735,000 | 812,000 | ||
| Tax | 4,312,000 | -1,257,000 | -7,518,000 | -2,858,000 | -3,846,000 | -2,382,000 | -4,883,000 | -1,807,000 | -2,170,000 | -1,768,000 | -2,459,000 | -2,104,000 | -2,076,000 | -3,918,000 | -1,469,000 |
| Stock | 1,533,000 | -1,930,000 | -845,000 | 4,130,000 | -3,052,000 | 3,545,000 | 1,363,000 | 3,217,000 | 1,489,000 | 451,000 | 75,000 | -264,000 | 1,108,000 | 1,571,000 | 2,973,000 |
| Debtors | -35,499,000 | 85,348,000 | -188,890,000 | 122,795,000 | 16,464,000 | 29,461,000 | 19,888,000 | 12,837,000 | 19,110,000 | -2,263,000 | 1,203,000 | 1,531,000 | -1,342,000 | 2,010,000 | 7,507,000 |
| Creditors | 1,739,000 | 6,631,000 | -2,871,000 | 4,441,000 | -3,036,000 | 1,619,000 | 3,928,000 | 413,000 | -953,000 | 593,000 | 215,000 | -253,000 | -2,395,000 | 2,032,000 | 1,501,000 |
| Accruals and Deferred Income | -8,456,000 | -4,090,000 | 11,968,000 | 1,276,000 | 1,094,000 | 1,332,000 | -3,331,000 | -1,807,000 | 7,894,000 | -2,338,000 | -11,806,000 | -21,903,000 | -5,350,000 | 17,333,000 | 29,992,000 |
| Deferred Taxes & Provisions | -5,258,000 | -1,467,000 | 4,085,000 | 341,000 | 1,672,000 | 1,054,000 | 2,150,000 | 145,000 | 1,262,000 | -147,000 | -22,000 | -2,443,000 | 7,866,000 | 1,282,000 | |
| Cash flow from operations | -4,343,000 | -61,670,000 | 221,363,000 | -102,593,000 | 14,229,000 | -8,874,000 | 3,782,000 | -2,114,000 | 2,531,000 | 10,597,000 | -660,000 | -15,118,000 | 11,603,000 | 32,891,000 | 30,770,000 |
| Investing Activities | |||||||||||||||
| capital expenditure | |||||||||||||||
| Change in Investments | -1,544,000 | -51,060,000 | 82,094,000 | -985,000 | 3,820,000 | -1,245,000 | -61,916,000 | 356,000 | 88,720,000 | 56,000 | 443,000 | 114,000 | 3,160,000 | ||
| cash flow from investments | |||||||||||||||
| Financing Activities | |||||||||||||||
| Bank loans | -4,250,000 | 250,000 | 886,000 | 3,114,000 | |||||||||||
| Group/Directors Accounts | 11,456,000 | 1,964,000 | -283,036,000 | 53,737,000 | 30,339,000 | 57,807,000 | 28,112,000 | 8,128,000 | 66,514,000 | 5,226,000 | 9,578,000 | 33,161,000 | |||
| Other Short Term Loans | 413,000 | -47,000 | -453,000 | -334,000 | -2,055,000 | 2,889,000 | |||||||||
| Long term loans | -18,523,000 | 16,548,000 | 146,917,000 | 61,985,000 | 51,042,000 | -16,546,000 | -13,895,000 | -926,000 | 41,109,000 | -1,517,000 | 656,000 | -10,225,000 | 450,000 | -8,018,000 | 38,018,000 |
| Hire Purchase and Lease Commitments | 1,000 | -49,000 | 10,000 | -1,490,000 | -168,000 | 1,897,000 | -1,000 | 1,000 | |||||||
| other long term liabilities | -40,000 | -33,000 | -858,000 | 931,000 | |||||||||||
| share issue | |||||||||||||||
| interest | -25,006,000 | -6,588,000 | -6,776,000 | -9,265,000 | -9,745,000 | -7,617,000 | -3,366,000 | -5,912,000 | -3,876,000 | -2,799,000 | -2,486,000 | -2,376,000 | -2,257,000 | -2,788,000 | -3,674,000 |
| cash flow from financing | -32,657,000 | 10,790,000 | -142,450,000 | 106,656,000 | 70,159,000 | 33,255,000 | 10,795,000 | 3,958,000 | 103,752,000 | -4,943,000 | 8,098,000 | 6,274,000 | -1,575,000 | -14,825,000 | 35,610,000 |
| cash and cash equivalents | |||||||||||||||
| cash | -9,935,000 | -2,720,000 | 1,136,000 | 8,574,000 | 3,745,000 | -1,776,000 | 6,178,000 | 70,000 | 1,127,000 | 807,000 | -3,816,000 | 3,471,000 | -697,000 | 1,014,000 | 577,000 |
| overdraft | -68,035,000 | 26,316,000 | 15,937,000 | 10,006,000 | 12,467,000 | -1,712,000 | -1,230,000 | 6,251,000 | -683,000 | 683,000 | |||||
| change in cash | -9,935,000 | -2,720,000 | 1,136,000 | 8,574,000 | 71,780,000 | -28,092,000 | -9,759,000 | -9,936,000 | -11,340,000 | 2,519,000 | -2,586,000 | -2,780,000 | -697,000 | 1,697,000 | -106,000 |
alliance pharmaceuticals limited Credit Report and Business Information
Alliance Pharmaceuticals Limited Competitor Analysis
Perform a competitor analysis for alliance pharmaceuticals limited by selecting its closest rivals, whether from the MANUFACTURING sector, other mega companies, companies in SN15 area or any other competitors across 12 key performance metrics.
alliance pharmaceuticals limited Ownership
ALLIANCE PHARMACEUTICALS LIMITED group structure
Alliance Pharmaceuticals Limited has 9 subsidiary companies.
Ultimate parent company
1 parent
ALLIANCE PHARMACEUTICALS LIMITED
03250064
9 subsidiaries
alliance pharmaceuticals limited directors
Alliance Pharmaceuticals Limited currently has 3 directors. The longest serving directors include Mr Andrew Franklin (Sep 2015) and Mr Alexander Duggan (Jun 2018).
| officer | country | age | start | end | role |
|---|---|---|---|---|---|
| Mr Andrew Franklin | United Kingdom | 58 years | Sep 2015 | - | Director |
| Mr Alexander Duggan | England | 54 years | Jun 2018 | - | Director |
| Mr Nicholas Sedgwick | United Kingdom | 52 years | May 2024 | - | Director |
P&L
December 2023turnover
125.2m
+8%
operating profit
-39.2m
-397%
gross margin
60.5%
-0.94%
turnover
Turnover, or revenue, is the amount of sales generated by a company within the financial year.
Balance Sheet
December 2023net assets
17.6m
-0.78%
total assets
364.2m
-0.18%
cash
7.8m
-0.56%
net assets
Total assets minus all liabilities
alliance pharmaceuticals limited company details
company number
03250064
Type
Private limited with Share Capital
industry
10890 - Manufacture of other food products n.e.c.
21200 - Manufacture of pharmaceutical preparations
incorporation date
September 1996
age
29
incorporated
UK
ultimate parent company
accounts
Full Accounts
last accounts submitted
December 2023
previous names
N/A
accountant
-
auditor
DELOITTE LLP
address
avonbridge house bath road, chippenham, wiltshire, SN15 2BB
Bank
LLOYDS BANK CORPORATE MARKETS
Legal Advisor
-
alliance pharmaceuticals limited Charges & Mortgages
A charge, or mortgage, refers to the rights a company gives to a lender in return for a loan, often in the form of security given over business assets.
We found 25 charges/mortgages relating to alliance pharmaceuticals limited. Currently there are 11 open charges and 14 have been satisfied in the past.
alliance pharmaceuticals limited Capital Raised & Share Issues BETA
When a company issues new shares, e.g. to new investors following a funding round, it is required to notify Companies House within one month of making an allotment of shares.
Click to start generating capital raising & share issue transactions for ALLIANCE PHARMACEUTICALS LIMITED. This can take several minutes, an email will notify you when this has completed.
alliance pharmaceuticals limited Companies House Filings - See Documents
| date | description | view/download |
|---|
